Strategy

Eisai positions tropical diseases, including Neglected Tropical Disease (NTDs) and malaria, as a key focus area alongside dementia and cancer. Guided by our human health care (hhc) concept, we are committed to developing new treatments and expanding access to medicines within this business domain.

Global health is a field closely related to health risks and poverty, which spreads in a chain reaction across the globe. To eliminate tropical diseases, international collaboration based on a long-term, sustainable perspective is essential. We are committed to developing new treatments to address medical needs based on cutting edge life sciences and to improve access to medicines for those in need. To this end, we collaborate with a range of stakeholders who bring diverse expertise and technologies, such as governments, international organizations, such as the World Health Organization (WHO), private companies, academia and research institutes, non-governmental organizations (NGOs), non-profit organizations (NPOs), and various foundations. Through this initiative, we are aiming to create a society where all individuals can equally enjoy being healthy and realize their fullest lives.

For lymphatic filariasis (LF), Eisai will continue to provide high-quality diethylcarbamazine (DEC) tablets to WHO free of charge, in line with the LF elimination goals outlined in the WHO’s “Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030”.In addition to supplying medicine, we will also continue our efforts to accelerate LF elimination through LF awareness-raising activities and support for the improvement public health infrastructure.

For malaria and NTDs, including Mycetoma, we are focusing on the research and development of compounds for target diseases, including discovery of new medicines and conducting clinical studies in endemic areas, through collaboration with academia, research institutions, and non-profit research and development organizations, such as Drug for Neglected Disease initiative (DNDi). These efforts are supported by funding from domestic and international foundations, including Global Health Innovative Technology Fund (GHIT Fund).

Additionally, Eisai is working to quantify the social impact of DEC tablets, including the recovery of working hours and reduction in healthcare expenses through the prevention of LF infection and diseases progression. While presenting sales revenue and profit from the free provision of DEC tablet is challenging, by visualizing its contribution to society as social impact, we aim to advance partnerships and attract investment opportunities.

Please see this link for details on Calculating the Social Impact of Efforts to Eliminate LF
Please see this link for details on our history in the field of global health

Eisai has established long-term objectives and KPIs for fiscal 2030 and are managing our progress, aiming for the elimination of diseases and reduction of health disparities through the creation of new treatments and expanded access in the field of global health.
Please see this link for details on long-term goals, KPIs, and risks in the field of global health.

Please see this link for details on our “Medium-term Business Plan and Its Progress” related to global health.